Nintedanib treatment for bleomycin-induced lung injury - First report

Although the antineoplastic agent bleomycin is known for more than 50 years, its exact pharmacological and side-effect mechanisms remain incompletely understood. The major limitation of bleomycin therapy is the risk of pulmonary toxicity which can be diverse, and potentially fatal in 10% of patients...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Dina Rnjak, Martina Batarilo Hađar, Dubravka Pelicarić, Tea Vukić, Mateja Janković Makek, Miroslav Samaržija, Ana Hećimović
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Elsevier 2023-01-01
Σειρά:	Respiratory Medicine Case Reports
Θέματα:	Nintedanib Bleomycin Lungs
Διαθέσιμο Online:	http://www.sciencedirect.com/science/article/pii/S2213007123001168
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!